title: Guidelines for the surveillance of localized renal cell carcinoma based on the patterns of relapse after nephrectomy.
abstract: OBJECTIVE
  We characterized relapse patterns in patients with sporadic renal cell carcinoma (RCC) following radical and partial nephrectomy, and developed surveillance guidelines.
  
  
  METHODS
  Between 1989 and 2000, 495 patients underwent nephrectomy for RCC at 1 of 5 Canadian referral centers. Median followup was 42 months.
  
  
  RESULTS
  The rate of relapse, time to relapse and site of relapse were associated with pathological stage. Five-year progression-free probability was 93% for pT1, 81% for pT2, 67% for pT3A and 57% for pT3B (p <0.001). Compared to patients with pT1-2 those with pT3A-B lesions had earlier relapse after nephrectomy (median 12 vs 26 months, p = 0.001) and were at higher risk for relapse at abdominal sites (14% vs 1.8%, p < 0.001). Abdominal relapse was detected in the absence of symptoms, abnormal biochemical profile or thoracic metastases detectable by chest x-ray in 7 patients (1.4%) overall, including 3 (0.9%) with pT1, 3 (4%) with pT3A and 1 (3%) with pT3B.
  
  
  CONCLUSIONS
  The risk and the pattern of relapse of RCC after nephrectomy are associated with pathological stage. For the surveillance of recurrent disease after nephrectomy we recommend annual clinical assessment and chest x-ray in pT1-2 cases. Patients with pT3A-B should be followed every 6 months for the first 3 years with clinical assessment and chest x-ray, and annual followup thereafter. The higher risk of abdominal relapse in patients with pT3A-B indicates that they should receive surveillance abdominal imaging. We recommend abdominal computerized tomography 6, 12, 24 and 36 months postoperatively.
authors.affiliation: Division of Urology, McGill University), Montréal, Québec, Canada.
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Stephenson
authors.forename: Michael P
authors.initials: MP
authors.lastname: Chetner
authors.forename: Keith
authors.initials: K
authors.lastname: Rourke
authors.forename: Martin E
authors.initials: ME
authors.lastname: Gleave
authors.forename: M
authors.initials: M
authors.lastname: Signaevsky
authors.forename: Bruce
authors.initials: B
authors.lastname: Palmer
authors.forename: James
authors.initials: J
authors.lastname: Kuan
authors.forename: Gerald B
authors.initials: GB
authors.lastname: Brock
authors.forename: Simon
authors.initials: S
authors.lastname: Tanguay
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002292:Carcinoma, Renal Cell / Q000473:pathology* / Q000601:surgery*; D003266:Continuity of Patient Care; D018572:Disease-Free Survival; D006801:Humans; D007680:Kidney Neoplasms / Q000473:pathology* / Q000601:surgery*; D008875:Middle Aged; D008991:Monitoring, Physiologic; D009364:Neoplasm Recurrence, Local / Q000473:pathology*; D009367:Neoplasm Staging; D009392:Nephrectomy; D011184:Postoperative Period